Dermatology

413.6K Papers

Follow See full results

Article Dermatology

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, Elisa Camela, Angelo Ruggiero

Summary: This study evaluated the effectiveness, safety, and tolerability of guselkumab in a real-life setting. The results showed that patients with psoriasis achieved significant clinical improvement with guselkumab treatment in a long-term setting, and the treatment was well tolerated.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study

Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini

Summary: Recent knowledge on the key role of IL-23/17 axis in psoriasis has led to the development of new biologic drugs, such as risankizumab. This study aimed to assess the efficacy and safety of risankizumab in patients who previously failed anti-IL-17 treatments. The results showed a significant reduction in psoriasis severity and improvement in nail psoriasis severity. The study confirmed the effectiveness and safety of risankizumab in these patients.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis

James G. Krueger, Iain B. McInnes, Andrew Blauvelt

Summary: Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in psoriasis, but safety concerns persist with current JAK inhibitors. TYK2, a member of the JAK family, may offer a potential target for safer and more effective therapies in psoriasis treatment.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

Najeeda Yasmeen, Laura M. Sawyer, Kinga Malottki, Lars-Ake Levin, Eydna Didriksen Apol, Gregor B. Jemec

Summary: This study compared the PASI outcomes of approved biologics and apremilast after 1 year of treatment. The results showed that risankizumab, brodalumab, and guselkumab were the most effective therapies. Additionally, these therapies were more effective than apremilast and other drugs in achieving PASI responses.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Review Dermatology

Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response

Husein Husein-ElAhmed, Martin Steinhoff

Summary: This study provides evidence that dupilumab is an effective treatment for prurigo nodularis (PN), with a later onset of clinical response compared to atopic dermatitis. Two months of therapy are required for itch relief, and complete remission is rarely achieved before 4 months of therapy. Atopic dermatitis-related PN patients require longer treatment than non-atopic dermatitis-related PN patients.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

L. Borradori, N. Van Beek, C. Feliciani, B. Tedbirt, E. Antiga, R. Bergman, B. C. Boeckle, M. Caproni, F. Caux, N. S. Chandran, G. Cianchini, M. Daneshpazhooh, D. De, D. Didona, G. M. Di Zenzo, M. Dmochowski, K. Drenovska, J. Ehrchen, M. Goebeler, R. Groves, C. Guenther, B. Horvath, M. Hertl, S. Hofmann, D. Ioannides, B. Itzlinger-Monshi, J. Jedlickova, C. Kowalewski, K. Kridin, Y. L. Lim, B. Marinovic, A. Marzano, J. -M. Mascaro, J. M. Meijer, D. Murrell, K. Patsatsi, C. Pincelli, C. Prost, K. Rappersberger, M. Sardy, J. Setterfield, M. Shahid, E. Sprecher, K. Tasanen, S. Uzun, S. Vassileva, K. Vestergaard, A. Vorobyev, I. Vujic, G. Wang, K. Wozniak, S. Yayli, G. Zambruno, D. Zillikens, E. Schmidt, P. Joly

Summary: The background provides detailed information about bullous pemphigoid (BP) and its impact on patients. The objective of the study is to update the guidelines for managing this disease. The results suggest that treatment should be tailored based on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the main treatment, while the use of doxycycline and dapsone is controversial. B-cell-depleting therapy and intravenous immunoglobulins can be considered in treatment-resistant cases. The final version of the guideline received consent from several patient organizations.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Review Dermatology

Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology CLEAR Derm Consensus Guidelines From the International Skin Imaging Collaboration Artificial Intelligence Working Group

Roxana Daneshjou, Catarina Barata, Brigid Betz-Stablein, M. Emre Celebi, Noel Codella, Marc Combalia, Pascale Guitera, David Gutman, Allan Halpern, Brian Helba, Harald Kittler, Kivanc Kose, Konstantinos Liopyris, Josep Malvehy, Han Seung Seog, H. Peter Soyer, Eric R. Tkaczyk, Philipp Tschandl, Veronica Rotemberg

Summary: The use of AI in dermatology is accelerating, and it is important to establish comprehensive criteria for development and evaluation to ensure fairness, reliability, and safety. In this consensus statement, experts provide guidelines for developers and reviewers to achieve clinically effective AI.

JAMA DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

Monkeypox emerges on a global scale: A historical review and dermatologic primer

Josh Bryer, Esther E. Freeman, Misha Rosenbach

Summary: The current monkeypox outbreak raises concerns about the potential of poxviridae to cause a zoonotic spillover and a pandemic. Previous fieldwork and research in Africa provide valuable knowledge for the global response to the current outbreak. However, the unusual clinical presentations of the disease have implications for its recognition. Dermatologists will play a crucial role in identifying and diagnosing infections, as well as educating and preparing frontline healthcare workers for early detection of new cases and clusters of monkeypox.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna

Summary: A study conducted in Italy comparing the effectiveness and safety of guselkumab and risankizumab in treating moderate-to-severe psoriasis found that both drugs showed similar efficacy and safety profiles, with no significant differences observed between the two treatments.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Review Dermatology

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis

James Krueger, Lluis Puig, Diamant Thaci

Summary: Generalized pustular psoriasis (GPP) is a rare and severe skin disorder without approved specific therapies. Current treatment options are based on limited evidence and recent advances have identified potential targets for targeted therapy based on improved understanding of the disease mechanisms and gene mutations associated with GPP.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

A Systematic Review on Classification, Identification, and Healing Process of Burn Wound Healing

Morteza Abazari, Azadeh Ghaffari, Hamid Rashidzadeh, Safa Momeni Badeleh, Yaser Maleki

Summary: The classification of wounds is crucial for diagnosis, management, and treatment selection. Burn injuries, caused by heat, cold, electricity, etc., are a type of wounds. Understanding the biological trend of wound healing and differences in healing processes among different wounds can reduce risks and minimize damage to injured tissue and organs.

INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS (2022)

添加到收藏夹

Review Dermatology

Treatment options for leishmaniasis

S. Pradhan, R. A. Schwartz, A. Patil, S. Grabbe, M. Goldust

Summary: Leishmaniasis is classified into cutaneous, mucocutaneous, and visceral forms, with the visceral form being the most dangerous. Treatment of leishmaniasis remains challenging with various drugs available, each differing in cost, toxicity, treatment duration, and emergence of drug resistance. Ongoing research is focused on exploring new drugs and treatment options for leishmaniasis.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic

Omer Kutlu, Habibullah Aktas, Isil Gogem Imren, Ahmet Metin

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers

Leonie W. Schelke, Peter Velthuis, Jonathan Kadouch, Arthur Swift

Summary: Using duplex ultrasonography and injection of hyaluronidase can improve the treatment outcome after a vascular adverse event with hyaluronic acid filler treatments.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

添加到收藏夹

Article Dermatology

Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in Keloids

Xuanyu Liu, Wen Chen, Qingyi Zeng, Baihui Ma, Zhujun Li, Tian Meng, Jie Chen, Nanze Yu, Zhou Zhou, Xiao Long

Summary: This research utilized single-cell RNA sequencing to uncover the cellular heterogeneity of keloid tissue, particularly significant expansion of fibroblast and vascular endothelial cell subpopulations. The roles of TGFb and Eph-ephrin signaling pathways in keloids were highlighted, with key regulators like TWIST1, FOXO3, and SMAD3 identified. Additionally, activation of tumor-related pathways in keloid fibroblasts and vascular endothelial cells may contribute to the malignant features of keloids.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

Benjamin Klein, Regina Treudler, Jan C. Simon

Summary: JAK inhibitors have shown promising results in treating various chronic inflammatory skin diseases through their ability to target proinflammatory cytokines released via the JAK-STAT pathway. Recent approvals of JAK inhibitors like Baricitinib, Upadacitinib, and Abrocitinib offer new systemic therapeutic options for moderate to severe atopic dermatitis patients. While these small molecules have demonstrated effectiveness, potential side effects and necessary laboratory examinations should be carefully considered.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Article Dermatology

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

J. Gutermuth, A. E. Pink, M. Worm, L. Soldbro, C. Bjerregard Oland, S. Weidinger

Summary: The study evaluated the efficacy and safety of tralokinumab plus TCS in adult patients with severe AD not adequately controlled with CSA or with contraindications to oral CSA, showing the treatment was effective and well tolerated.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations

A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara Pinton, S. Christen-Zach, M. Deleuran, M. Dittmann, C. Dressler, A. H. Fink-Wagner, N. Fosse, K. Gaspar, L. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. G. Mortz, A. Nast, U. Nygaard, M. Redding, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra-Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, C. Flohr

Summary: The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. It provides recommendations and detailed information on basic therapy and other treatments for atopic eczema, covering various aspects such as provocation factors, dietary interventions, and occupational and psychodermatological aspects. The guideline also includes specific guidance for pediatric and adolescent patients, as well as pregnant or breastfeeding women.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Review Dermatology

Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

Kevin Phan, Steven Phan, Stephen Shumack, Monisha Gupta

Summary: JAK inhibitors show promising effectiveness in treating vitiligo, especially in patients with facial involvement. Concurrent UVB phototherapy can enhance the efficacy of JAK inhibitor therapy.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

K. Kabashima, T. Matsumura, H. Komazaki, M. Kawashima

Summary: Long-term administration of nemolizumab in patients with inadequately controlled moderate-to-severe pruritus in AD showed continuous improvement in pruritus, signs of AD, and quality of life for up to 68 weeks, with a favorable safety profile, based on two long-term phase III studies.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.